Semaglutide is also demonstrated to have prospective kidney Advantages in T2D patients driven partially by its hypoglycemic and cardioprotective effects [twelve]. As a consequence of its reduction in blood glucose concentrations, semaglutide as well as other GLP-1-RA’s can from time to time result in hypoglycemic activities. On the other hand,